コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 -HS may expand KIT+ progenitors in vitro for regenerative therapy.
2 challenges of this new technology for future regenerative therapy.
3 er injury and discuss their implications for regenerative therapy.
4 o provide a novel route for cardiac cellular regenerative therapy.
5 rogenitor cells are an attractive target for regenerative therapy.
6 this promising new technology into a proven regenerative therapy.
7 ific and clinical position of cardiovascular regenerative therapy.
8 ell type for potential use in cardiovascular regenerative therapy.
9 s should be done before they can be used for regenerative therapy.
10 ing human cardiac development as well as for regenerative therapy.
11 g (MRI) to evaluate a hydrogel-based cardiac regenerative therapy.
12 l stem cells hold promise for cardiovascular regenerative therapy.
13 is may enhance cardiac-progenitor cell-based regenerative therapy.
14 ssociated with GCA and no previous report of regenerative therapy.
15 polysaccharide-mediated bone resorption) and regenerative therapy.
16 onarily conserved and could be exploited for regenerative therapy.
17 mportant dental stem cells for future dental regenerative therapy.
18 1 and 2 mobility, will respond favorably to regenerative therapy.
19 control the clinical outcomes of periodontal regenerative therapy.
20 ally provide a limitless source of cells for regenerative therapy.
21 s may be significant in clinical outcomes of regenerative therapy.
22 istic effect of EMPs and BPBM in periodontal regenerative therapy.
23 for significant clinical improvements after regenerative therapy.
24 iologics enhance the outcomes of periodontal regenerative therapy.
25 Bridging knowledge gaps could enable regenerative therapy.
26 betes that is potentially reversible through regenerative therapy.
27 inically relevant cell-free therapeutics for regenerative therapy.
28 to facilitate the development of mRNA-based regenerative therapy.
29 autologous minced muscle grafting (MMG) as a regenerative therapy.
30 promising approach to expand stem cells for regenerative therapy.
31 rug discovery, disease modeling, and cardiac regenerative therapy.
32 s provide an excellent pool of molecules for regenerative therapy.
33 ould provide a promising source of cells for regenerative therapy.
34 and are therefore not a promising target for regenerative therapy.
35 edures is an important aspect of periodontal regenerative therapy.
36 ow this occurs is highly relevant to cardiac regenerative therapy.
37 defects may be successfully treated with non-regenerative therapy.
38 stering the path to novel approaches in bone-regenerative therapy.
39 ) metabolism may be a target for periodontal regenerative therapies.
40 xtensively used to enhance tissue repair and regenerative therapies.
41 scovery of stem cell therapeutics to support regenerative therapies.
42 the heart spurred enthusiasm for cell-based regenerative therapies.
43 ures and have implications for other bladder regenerative therapies.
44 us for exploring mechanobiology paradigms in regenerative therapies.
45 epresents an important step toward potential regenerative therapies.
46 wth potential is of broad interest for tooth regenerative therapies.
47 greatly aid in the development of effective regenerative therapies.
48 d highlights pathways for the development of regenerative therapies.
49 repair and is therefore a primary target of regenerative therapies.
50 st that BTC could be a good candidate to aid regenerative therapies.
51 hat has dramatic implications for cell-based regenerative therapies.
52 ncing their quality should be considered for regenerative therapies.
53 eld potential new targets and strategies for regenerative therapies.
54 cells in mammals and developing novel renal regenerative therapies.
55 ssues and the potential effectiveness of new regenerative therapies.
56 ypes and hence have tremendous potential for regenerative therapies.
57 lls and are the rational target for clinical regenerative therapies.
58 nd aid in the development of stem cell-based regenerative therapies.
59 tracer reporter probes for tracking cellular regenerative therapies.
60 ices to promote vascularization for directed regenerative therapies.
61 al elements when designing human tissues for regenerative therapies.
62 INFUSE bone grafts for periodontal and oral regenerative therapies.
63 tor cells with the potential for safe use in regenerative therapies.
64 nal stem cells can be activated for possible regenerative therapies.
65 iation that makes them potential targets for regenerative therapies.
66 erable for assessing efficacy of periodontal regenerative therapies.
67 ontained versus non-contained, using various regenerative therapies.
68 of factors involved in designing predictable regenerative therapies.
69 ort superiority or equivalency between the 2 regenerative therapies.
70 sis in vivo to facilitate drug discovery and regenerative therapies.
71 bioactive agents is important for improving regenerative therapies.
72 ap, hemisection, tunneling or extraction, to regenerative therapies.
73 mpounds might prove useful in protective and regenerative therapies.
74 g thus emerging leads for the development of regenerative therapies.
75 ll facilitate the development of much-needed regenerative therapies.
76 nd model diseases, but also hold promise for regenerative therapies.
77 but also opens avenues for developing novel regenerative therapies.
78 veloping next-generation liquid biopsies and regenerative therapies.
79 enge, driving the exploration of alternative regenerative therapies.
80 es for leveraging these findings to progress regenerative therapies.
81 that HS glycomimetics have the potential for regenerative therapies.
82 ide mechanistic insights into developing new regenerative therapies.
83 ing pathways may have applications in future regenerative therapies.
84 SHF-FBs are a promising source of cells for regenerative therapies.
85 system and offers great promise for emerging regenerative therapies.
86 ssue malformation that might inform targeted regenerative therapies.
87 nce to the development of cell-based cardiac regenerative therapies.
88 nd may have broad implications for inner ear regenerative therapies.
89 affordable, and less side-effect-prone bone regenerative therapies.
90 ng will inform future endothelial cell-based regenerative therapies.
91 regeneration may enable development of novel regenerative therapies.
92 ital cardiac malformations and designing new regenerative therapies.
93 direct access to the nerve to deliver novel regenerative therapies.
94 sis holds promise as the basis for new renal regenerative therapies.
95 nitely, making them an attractive source for regenerative therapies.
96 c cell types for basic laboratory studies or regenerative therapies.
97 ces for improving stem cell fate in clinical regenerative therapies.
98 this ability may provide insights into human regenerative therapies.
99 for disease modelling, drug development and regenerative therapies.
100 ation, basic developmental studies or future regenerative therapies.
101 of targeted strategies that expand HSCs for regenerative therapies.
102 estoration of beta-cells is a major goal for regenerative therapies.
103 ion of functional vision through optic nerve regenerative therapies.
104 may improve the efficacy of stem-cell-based regenerative therapies.
105 ls (HSCs) are essential for many life-saving regenerative therapies.
106 defects may be treated predictably with non-regenerative therapies.
107 ate MSC population for designing predictable regenerative therapies.
108 monitor the fate and action of cells used in regenerative therapies.
109 drug toxicology tests, and advance potential regenerative therapies.
110 inical application in myocardial disease and regenerative therapies.
111 ns critical for the development of potential regenerative therapies.
112 ration, and therefore they could be used for regenerative therapies.
113 novel perspective for reinterpreting cardiac regenerative therapies.
114 ent stem cells will form the basis of future regenerative therapies.
115 cal use could be considered for craniofacial regenerative therapies.
116 ssary for the design of improved periodontal regenerative therapies.
117 ecular materials a great platform to develop regenerative therapies.
118 , which supports the relevance of exploring 'regenerative' therapies.
119 ealth with a reduced support, whereas, after regenerative therapy, a successful outcome was described
120 harmacodynamic implications in the design of regenerative therapies aimed at increasing beta-cell rep
121 ia and help clarify potential strategies for regenerative therapies aimed at treating retinal dystrop
124 or the widely anticipated next generation of regenerative therapies and as such are pioneering the st
125 olangiocyte organoids show great promise for regenerative therapies and in vitro modeling of bile duc
126 s for the treatment of furcation defects via regenerative therapies and the conduction of future stud
129 a conscious approach to the development of a regenerative therapy and, by deciphering the thread conn
130 ing developmental heart disorders, enhancing regenerative therapies, and mitigating cardiovascular di
131 creening, modeling rare disorders, designing regenerative therapies, and understanding disease pathog
132 tform may apply in drug screening, beta cell regenerative therapies, and/or diagnostic imaging in pat
135 subgingival microbiota was examined prior to regenerative therapy, and the membrane microbiota was ex
138 fundamental mechanobiological processes and regenerative therapies are provided, along with a discus
139 inoglycans (GAGs) offer exciting options for regenerative therapies as they allow for the electrostat
140 eview of all pertinent literature discussing regenerative therapy at the time of tooth extraction or
142 instays of cardiac therapies, but eventually regenerative therapies based on fundamental regenerative
144 cells (hDPSCs) are attractive candidates for regenerative therapy because they can be easily expanded
145 ell-derived progenitors offers potential for regenerative therapies but is often limited by developme
146 be important not only for the development of regenerative therapies, but also for understanding the a
147 nsidered to be an attractive cell source for regenerative therapies, but maintaining multipotency and
148 ure-induced injury may help to advance brain regenerative therapies by using either transplanted or e
151 ts that fail to heal, a condition where bone-regenerative therapies could provide substantial clinica
152 mising tool for human developmental biology, regenerative therapies, disease modeling, and drug disco
153 lls (hiPSCs) are a robust source for cardiac regenerative therapy due to their potential to support a
154 rgeting microRNAs (miRNAs) holds promise for regenerative therapy due to their profound regulatory ef
156 ired regenerative response, to develop novel regenerative therapies for APAP-induced acute liver fail
157 ical Wnt signaling as a potential target for regenerative therapies for APAP-induced acute liver fail
165 mation that is crucial to the development of regenerative therapies for human tissues and organs.
172 tion of these properties could lead to novel regenerative therapies for traumatic injuries and drug t
175 senescent hCPCs will improve the outcome of regenerative therapy for a substantial patient populatio
178 To improve the efficacy and outcomes of regenerative therapy for furcation defects, the use of p
180 rane for guided tissue regeneration (GTR) as regenerative therapy for intrabony defects in humans and
181 hment gain, and defect fill when employed as regenerative therapy for intraosseous lesions in humans.
185 e conclusions regarding the effectiveness of regenerative therapy for the treatment of furcation defe
186 neration after the application of a combined regenerative therapy for the treatment of maxillary faci
187 ed since the first successful application of regenerative therapy for treatment of periodontal diseas
188 ther distinguish the analgesic mechanisms of regenerative therapies from those of cellular replacemen
190 therapeutic options are urgently needed, but regenerative therapies have remained an unfulfilled prom
191 t, electrochemistry, biologics delivery, and regenerative therapy have been extensively reviewed.
194 em/progenitor cells hold great potential for regenerative therapies; however, the mechanisms regulati
196 significant potential for antimicrobial and regenerative therapies in bacterial-resistant infections
197 n myelin development and their potential for regenerative therapies in multiple sclerosis and dysmyel
199 tial to improve transplantation outcomes for regenerative therapies in the setting of cardiovascular
200 attractive extragonadal stem cell source for regenerative therapies in the testis but their therapeut
201 s to be a useful and beneficial material for regenerative therapy in Class II furcation type periodon
202 long-term (2 to 5 year) clinical results of regenerative therapy in clinical private practice using
207 ogenitor cells (CPCs) is being evaluated for regenerative therapy in older patients with ischaemic he
216 he available evidence, it was concluded that regenerative therapy is a viable option to achieve predi
217 still needed to determine whether stem cell regenerative therapy is an effective treatment strategy
219 In order to design predictable periodontal regenerative therapies, it is important to understand th
220 ng laser irradiation during peri-implantitis regenerative therapy may aid in better probing PD reduct
224 l-mediated healing processes have made these regenerative therapies more clinically viable and will c
226 /progenitors have considerable potential for regenerative therapies of liver, bile duct, and pancreat
228 rategies targeting the RIPK3 pathway can aid regenerative therapies of photoreceptor transplantation.
233 Systemic DOXY, 200 mg/day for 7 days, after regenerative therapy of infrabony defects did not result
236 Early management of intrabony defects with regenerative therapies offers the greatest potential for
237 The clinical selection and application of a regenerative therapy or combination of therapies for per
241 n of new cell types for disease modeling and regenerative therapies, reprogramming remains a rare cel
242 d rational efforts to develop cell-based and regenerative therapies require knowledge of the molecula
243 Development of highly effective cardiac regenerative therapies requires connecting and coordinat
245 Improving cardiac function through stem-cell regenerative therapy requires functional and structural
246 , as this is a crucial step toward advancing regenerative therapy research for many intractable disor
248 domized controlled clinical trials comparing regenerative therapy (seven DBM, 22 BRG, and 26 GTR) to
250 igenesis and, thus, their implementation for regenerative therapy should be carefully considered in p
254 oratory research such as gene, stem cell, or regenerative therapies targeting congenital or acquired
257 echanistically-targeted immunomodulatory and regenerative therapies that are emerging from basic scie
258 e development of characterization assays for regenerative therapies that could be integrated into a g
259 ignificant efforts have been directed toward regenerative therapies that may facilitate neuronal repa
262 lls provides a valuable strategy for cardiac regenerative therapy that avoids the need for preparing
263 e development of a small-molecule epigenetic regenerative therapy that combines a demethylating agent
264 hip or sham chip placement one week prior to regenerative therapy that included graft placement and s
265 variety of common stressors associated with regenerative therapies, thereby motivating further inves
266 long-standing T1D and a possible target for regenerative therapies to expand beta-cell function in d
268 treatment to other more traditional forms of regenerative therapy to determine its comparative effica
269 man neural stem cells (hNSCs) is a promising regenerative therapy to promote remyelination in patient
270 or developing potential drug treatments, and regenerative therapies using in-vitro culture platforms.
271 o describe the progress in cardiac stem cell regenerative therapy using adult stem cells and to highl
272 caused by periodontitis are often treated by regenerative therapy using autografts and/or allografts.
273 ient received surgical therapy consisting of regenerative therapy using bioactive glass compared to o
274 (RCTs) reporting the outcomes of periodontal regenerative therapy using biologics for the treatment o
276 Within the limitations of the present study, regenerative therapy using either EMD + DBBM or CM + DBB
280 he outcome and predictability of periodontal regenerative therapies, we have focused on determining t
282 em cells are fundamental units for achieving regenerative therapies, which leads naturally to a theor
283 al changes in rat models following localized regenerative therapies, which may not be detected by con